-agonists, 586
for AECOPD, 1408
for hyperkalemia, 587t
and hypokalemia, 583t
Betaxolol (Betoptic), 1151
adverse effects of, 1158
alternative therapy, 1158
initial therapy, 1157
patient education, 1157
Bethanechol, 1974, 2163t
prokinetic agents, 508
Betoptic (see Betaxolol)
Bevacizumab (Avastin), 469t, 1972, 1991–1992, 2064, 2064t, 2065
for colon cancer, 2073, 2078
and hypertension, 1990
for metastatic colorectal cancer, 1169
Bexarotene, 470t, 942t
Biaxin (see Clarithromycin)
Bicalutamide, 2090, 2093
Bicarbonate (sodium bicarbonate), 643, 977
adverse effects of, 361
-carbonic acid system, 611
hyperkalemia and, 586, 587t
in metabolic acidosis, 562–563
for preventing SRMB, 515t
for salicylate toxicity, 70
for TCA toxicity, 77–78
BiDil (see Isosorbide dinitrate (BiDil))
Biguanide (Metformin)
adverse effects of, 1112
contraindications and precautions of, 1112–1113
dosage and clinical use of, 1113
drug interactions, 1113
efficacy of, 1113
mechanism of action, 1112–1113
pharmacokinetics of, 1112
for polycystic ovary syndrome, 1012t
for type 2 diabetes, 1140
Bile acid resins
adverse effects, 127
clinical pearls, 127
drug interactions, 127
efficacy, 127
mechanism of action, 126, 126f
pharmacokinetics/pharmacodynamics, 127
place in therapy, 127
Bilirubin, 30, 30f
blood chemistry reference values for, 19t
Bimatoprost (Lumigan), 1151
for ocular hypertension, 1151
Biperiden
for Akathisia, 1800t
for Parkinsonism, 1799
Biphosphonates, for hypercalcemia, 589t, 590
Bisacodyl, 2159t
for end-of-life care, 87
Bismuth salt, 486, 496–497
Bismuth subsalicylate (BSS)
for gastroenteritis, 2161
for Helicobacter pylori, 493–494t
for infectious diarrhea, 1449
Bisoprolol
in HFrEF, 287–288
in hypertension, 159t
Bisphosphonates, 2038, 2283–2284, 2286–2287
and dyspepsia, 487
GERD and, 503t
for osteoporosis, 2271
for prostate cancer, 2096
Bivalirudin, 254
for ACS, 239t
for heparin-induced thrombocytopenia, 178
in patients with HIT, 657
Black cohosh (Cimicifuga racemosa), 1030
Blenoxane (see Bleomycin)
Bleomycin (Blenoxane), 469t, 1978t, 1982t, 1987, 1991t, 1993, 1994t, 1995, 1977, 2040t
gonadal toxicity of, 1998
for HL, 2041
Boceprevir, 120t, 128
for HAV, 1687
Bonine (see Meclizine)
BOOSTRIX, 1357
Borates, 1626
Boric acid, for VVC, 1526
Bortezomib (Velcade), 469t, 2037t, 2038
neurotoxicity of, 1985t
peripheral nerve toxicity of, 1986
plus dexamethasone, 2037t
Bosentan, 924, 942t
for pulmonary HTN, 266
Bosutinib, 470t
Botulinum toxin A, 1271t, 1272
BranchAmin, 794t
Brentuximab vedotin, 469t
Breo Ellipta (fluticasone furoate/vilanterol), for chronic asthma, 396
Brevibloc (see Esmolol)
Brexpiprazole (Rexulti), 1789, 1791t
for Akathisia, 1799
Brimonidine (Alphagan), 1152
Brinzolamide (Azopt), 1152
Brisdelle (see Paroxetine mesylate)
Bromocriptine (Parlodel), 1250t, 1254t, 2266
and lactation, 1000
for type 2 diabetes, 1131
B
r
o
n
c
h
o
d
i
l
a
t
o
r
s
,
fo
r
C
O
P
D
,
4
1
6
–
4
1
7
,
4
2
3
B
S
S
(
s
e
e
B
i
s
m
u
t
h
s
u
b
s
a
l
i
c
yl
a
t
e
(
B
S
S
)
)
B
u
d
e
s
o
n
i
d
e
,
4
4
1
t
fo
r
a
lle
r
g
ic
r
h
init
is
,
4
4
2
fo
r
B
P
D
,
2
1
7
6
fo
r
c
hr
o
nic
a
s
thma
,
3
9
5
,
3
9
6–
3
9
7
fo
r
C
O
P
D
,
4
2
0
t
fo
r
in
fla
mma
t
o
r
y
b
o
w
e
l
dis
e
a
s
e
,
5
2
1
t
B
u
d
e
s
o
n
i
d
e
/
fo
r
m
o
t
e
r
o
l
(
S
y
m
b
i
c
o
rt
)
,
3
9
6
B
u
m
e
t
a
n
i
d
e
,
5
8
0
,
6
4
7
fo
r
H
F
,
2
7
7
B
u
p
i
v
a
c
a
i
n
e
,
1
1
7
7
t
B
u
p
r
e
n
o
rp
h
i
n
e
,
1
1
8
7
t
do
s
a
g
e
o
f,
1
1
9
9
t
fo
r
op
io
id
w
ith
dr
a
w
a
l
s
yn
dr
o
me
,
1
8
7
8
,
1
8
7
9
p. 2
2
9
3
p. 2
2
9
4
B
u
p
r
o
p
i
o
n
,
1
8
2
7
fo
r
A
D
H
D
,
1
8
7
1
fo
r
d
e
p
r
e
s
s
iv
e
dis
o
r
d
e
r
s
,
1
8
1
9
t
,
1
8
2
0
t
,
1
8
2
1
t
fo
r
dia
b
e
t
e
s
,
2
2
2
6
t
B
u
p
r
o
p
i
o
n
/z
o
n
i
s
a
m
i
d
e
E
R
,
7
6
4
fo
r
b
ip
o
la
r
d
e
p
r
e
s
s
io
n
,
1
8
3
7
a
n
d
s
le
e
p
,
1
7
7
4
fo
r
s
mo
kin
g
c
e
s
s
a
t
io
n
,
1
9
0
9
s
u
s
t
a
in
e
d
-
r
e
le
a
s
e
,
1
9
1
4
,
1
9
1
9
,
1
9
2
0–
1
9
2
2
,
1
9
2
4
B
u
S
p
a
r
(
s
e
e
B
u
s
p
i
r
o
n
e
)
B
u
s
p
i
r
o
n
e
(
B
u
S
p
a
r)
,
1
0
2
7
t
,
1
7
3
8
t
,
1
7
3
9
,
1
7
4
0
,
1
7
4
6
v
s. b
e
nz
o
dia
z
e
p
in
e
s
,
1
7
4
6
a
n
d
e
ld
e
r
ly
,
1
7
3
9
fo
r
P
M
D
D
,
1
0
2
5
B
u
s
u
l
fa
n
(
B
u
s
u
l
fe
x
,
M
yl
e
r
a
n
)
,
4
6
9
t
,
4
7
0
t
,
1
9
9
4
t
,
1
9
9
6
t
B
u
t
e
n
a
fi
n
e
,
1
6
2
4
t
B
u
t
o
c
o
n
az
o
l
e
,
1
6
2
4
t
fo
r
V
V
C
,
1
5
2
5
t
B
u
t
y
r
o
p
h
e
n
o
n
e
,
1
7
8
9
t
CC
a
b
azi
t
a
x
e
l
(
J
e
v
t
a
n
a)
,
4
6
9
t
p
e
r
ip
h
e
r
a
l
n
e
r
v
e
t
o
x
ic
ity
o
f,
1
9
8
6
fo
r
p
r
o
s
t
a
t
e
c
a
n
c
e
r
,
2
0
9
5
C
a
b
o
z
a
n
t
i
n
i
b
,
4
7
0
t
C
a
ffe
i
n
e
,
7
6
5
t
,
9
4
2
t
fo
r
a
p
n
e
a
,
2
1
8
9
fo
r
B
P
D
,
2
1
9
0
drug
int
e
r
a
c
t
io
n
w
ith
s
mo
kin
g
,
1
9
0
6
t
a
n
d
h
e
a
r
tb
ur
n
,
9
7
7
fo
r
I
D
H
,
6
5
7
a
n
d
lith
ium
,
1
8
4
3
t
a
n
d
p
r
e
gn
a
n
c
y
,
9
7
0
“
C
a
i
n
e
”
a
n
e
s
t
h
e
t
i
c
s
,
8
2
2
t
C
a
l
a
m
i
n
e
l
o
t
i
o
n
,
8
2
1
Calcijex, 622
Calcimimetics, 622–623
Calcineurin inhibitors, 635–636, 721–722
for FSGS patients, 628–629
induced nephrotoxicity, 729
Calcipotriene, for psoriasis, 835t, 837–838
Calcitonin, 2277t, 2284
for hypercalcemia, 589t, 590
for osteoporosis, 2271
Calcitriol, 621–622
for psoriasis, 835t, 838
Calcium, 26–27, 1986
blood chemistry reference values for, 18t
and BP, 134
and children, 2140t
for endometriosis, 1021
homeostasis, 586–587
hypercalcemia, 588–591
for PMS, 1024
and pregnancy, 968
recommended daily allowance, 969
and respiratory alkalosis, 1672
role of, 586
Calcium acetate, 620t
Calcium carbonate, 620t
Calcium-channel blockers (CCBs), 171, 211, 918, 993
for ACS, 239t
for AF, 314
in anginalsyndromes, 216t
CAD and, 147
diabetes and, 155–156
dihydropyridines, 155
GERD and, 503t
hemodynamic and electrophysiologic profile, 223t
for HF, 271–272
for hypertension, 140, 155–156, 156t
for hyperthyroidism, 1057, 1059t
nondihydropyridines, 155
in patients with CKD, 617
for pregestational diabetes, 979
for PSVT, 320
for thyroid storm, 1067
vasospastic and classic exertional angina, 222
Calcium gluconate, 587t
Campath (see Alemtuzumab)
Camphor, 1626, 1627
Canagliflozin, 1129–1130
Canakinumab, 903, 913
Canasa, 523t
Candesartan, 1242
for HF, 271, 283
for hypertension, 154t
Candicidin, 1626
Cangrelor, 246–247t
for ACS, 239t
for thrombotic events reduction, 244
Cannabinoids, 1224
for CINV, 473
Cannabis, 1783, 1783t
Canrenone, 581
Canthaxanthin, 856
Capecitabine (Xeloda), 470t, 1978t, 1991t
Capoten (see Captopril)
Capreomycin, for tuberculosis, 1430t
Caprylic acid, 1626
Capsaicin, 1187t
for neuropathic pain, 1188
for OA, 869
Capsaicin cream, 1182t
for PHN, 1654
Capsaicin patch, 1182t, 1654
Captopril (Capoten), 171, 257, 281–282, 281t, 336t, 2223
for BP, 339
and hyperkalemia, 584–585
in hypertension, 153t
Carba, 822t
Carbachol (Isopto Carbachol), 1152
Carbamazepine (CBZ), 42, 58, 58t, 214, 942t, 1181t, 1187t, 1279t, 1284t, 1743, 1754, 1837, 2261t
for acute mania, 1844–1845
autoinduction of metabolism of, 1282
bioequivalence of generic dosage of, 1282
for bipolar disorder, 1849t
for epilepsy, 57
extended-release forms of, 1282
for HAV, 1688
and hematologic toxicity, 1281
hepatotoxicity with, 1281–1282
initiation and dosage of, 1281
lamotrigine and, 1286–1287
and lithium, 1843t
for nocturnal leg cramps, 173
for ocular emergencies, 1160t
pharmacokinetics of, 1282
for schizophrenia, 1809
for seizures, 1281–1282
teratogenic effects, 973t
valproate and, 1296
Carbapenem
for febrile neutropenia, 1561
for skin and soft tissue infections, 1552
for UTI, 1497t
Carbidopa–levodopa (enteral suspension) (Duopa), for Parkinson’s disease, 1250t
Carbidopa–levodopa (CR) (Sinemet CR), for Parkinson’s disease, 1250t, 1260
Carbidopa–levodopa (ER) (Rytary), for Parkinson’s disease, 1250t, 1260–1261
Carbidopa–levodopa ODT (Parcopa), for Parkinson’s disease, 1250t
Carbonyl iron, 1930
Carboplatin (Paraplatin), 469t, 475, 1991t, 2065
for blood progenitor cell rescue, 2005
for NSCLC, 2062t, 2063t, 2064t
for SCLC, 2068t
Carboprost tromethamine, for postpartum hemorrhage, 997–998, 997t
Cardene IV (see Nicardipine)
Cardiac resynchronization therapy (CRT), 272
Carfilzomib, 469t, 2038
Cariprazine (Vraylar), 1797t, 1845
for acute mania, 1845t
for schizophrenia, 1789, 1791t
Carisoprodol, 1186t
Carmustine (BiCNU), 469t, 1979t, 1987, 1991, 1991t, 1994t, 1996, 1996t
and cranial neuropathies, 1987
Carteolol (Ocupress), 1151
Carvedilol, 258
in HFrEF, 287
for hypertension, 158–159, 159t
in peri-infarction period, 253, 258
Caspofungin, 1569, 1624t, 1625, 1632, 1633, 1634, 1640, 1641
adverse effects of, 1334t
dosing of, 1336t
for fungal endocarditis, 1400
renal failure, dosing of drugs, 675
Catapres (see Clonidine)
Catechol-O-methyltransferase inhibitors (COMT), 1262–1264
pharmacologic and pharmacokinetic properties of, 1263t
Catecholamines, for septic shock, 371
Cathelicidins, 1626
CBZ (see Carbamazepine (CBZ))
CCBs (see Calcium-channel blockers (CCBs))
p. 2294
p. 2295
Ceclor (see Cefaclor)
Cedax (see Ceftibuten)
Cefaclor (Ceclor), 1325t
for chronic antimicrobial therapy, 1499t
for UTI, 1489t
Cefadroxil (Duricef), 1325t
Cefamandole (Mandol), 1325t
Cefazolin (Ancef), 658, 661, 662, 1165, 1325t, 1548
for aerobic gram-positive cocci, 1326t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
dosing of, 1336t
for gram-negative aerobes, 1327t
for PVE, 1392t
for pyelonephritis, 995
renal failure, dosing of drugs, 675–676
for skin and soft tissue infections, 1548
for surgical procedures, 1345t, 1346, 1348–1349
for UTI, 1497t
Cefdinir (Omnicef), 1325t
Cefditoren (Spectracef), 1325t
Cefepime (Maxipime), 1325t
for aerobic gram-positive cocci, 1326t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
for CNS infections, 1373t
for cystic fibrosis, 461t
dosing of, 1336t
for febrile neutropenia, 1561
for gram-negative aerobes, 1327t
for gram-negative bacillary meningitis, 1378
for skin and soft tissue infections, 1550
for UTI, 1497t
Cefixime (Suprax), 1325t
for disseminated gonococcal infection, 1514
for shigellosis, 1456
for typhoid fever, 1456
for uncomplicated gonorrhea, 1508
Cefizox (see Ceftizoxime)
Cefonicid (Monocid), 1325t
Ceforanide (Precef), 1325t
Cefotaxime (Claforan), 1325t
for anaerobes, 1328t
and biliary pseudolithiasis, 1375
for CNS infections, 1373t
for NEC, 2183
for sepsis, 2186t
for UTI, 1497t
Cefotetan (Cefotan), 1325t
for anaerobes, 1328t
for chorioamnionitis, 996
for PID, 1512–1513t
Cefoxitin (Mefoxin), 1325t
for chorioamnionitis, 996
for PID, 1512–1513t
for surgical procedures, 1345t
for UTI, 1497t
Cefpodoxime proxetil (Vantin), 1325t
for UTI, 1489t
Cefprozil (Cefzil), 1325t
Ceftaroline (Teflaro), 1325t, 1371, 1393
for aerobic gram-positive cocci, 1326t
for gram-negative aerobes, 1327t
for skin and soft tissue infections, 1549
for UTI, 1497t
Ceftazidime (Fortaz), 462, 661, 663, 671, 1325t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
for cystic fibrosis, 461t
dosing of, 1336t
for febrile neutropenia, 1561
for gram-negative aerobes, 1327t
for gram-negative bacillary meningitis, 1378
renal failure, dosing of drugs, 667–668
for skin and soft tissue infections, 1550
for UTI, 1497t
Ceftazidime-avibactam, 1327t
Ceftibuten (Cedax), 1325t
Ceftin (Cefuroxime axetil), 1325t
Ceftizoxime (Cefizox), 1325t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
Ceftolozane/tazobactam (Zerbaxa), 1325t, 1371, 1401
for gram-negative aerobes, 1327t
Ceftriaxone (Rocephin), 549, 690, 1325t, 1371, 1376, 1401, 1720, 1723, 2131t
and aminoglycoside, 1390
for anorectal gonorrhea, 1511
and biliary pseudolithiasis, 1375
for CNS infections, 1373t
for disseminated gonococcal infection, 1514
dosing of, 1336t
for endocarditis, 1390
for neonatal DGI, 1514
for skin and soft tissue infections, 1549
for tularemia, 1723
for typhoid fever, 1455
for uncomplicated gonorrhea, 1508t, 1509
for UTI, 1497t
Cefuroxime (Zinacef), 1325t, 2131t
for aerobic gram-positive cocci, 1326t
for gram-negative aerobes, 1327t
for N. meningitides, 1374
for UTI, 1497t
Cefuroxime axetil (Ceftin), 1325t, 1720
Cefzil (see Cefprozil)
Celecoxib, 55, 490, 707, 870–871, 870t, 887, 888t
Celexa (see Citalopram)
Central α2
-agonists, for hypertension, 140
Cephalexin (Keflex), 977, 1325t
for chronic antimicrobial therapy, 1499t
for pyelonephritis, 977
for skin and soft tissue infections, 1547
for UTI, 1489t
Cephalosporins, 662, 685–686, 1372, 1720, 1725
adverse effects of, 1332t
for cardiac surgery prophylaxis, 1391–1392
for chorioamnionitis, 996
for CNS infections, 1373t
during pregnancy, 977
for tularemia, 1725
for uncomplicated gonorrhea, 1508t, 1509
for UTI, 1497t
Cephalothin, 661, 662
Ceritinib, 470t
Certolizumab
for CD, 529
pegol, 524, 881, 882, 895, 896t
for inflammatory bowel disease, 522t
Cerubidine (see Daunorubicin)
Cervarix, 1359
Cesamet (see Nabilone)
Cetilistat, 764
Cetirizine (Zyrtec), 433t
fo
r
r
h
init
is
,
4
3
7
a
n
d
s
le
e
p
,
1
7
6
6
C
e
t
u
x
i
m
a
b
(
E
rb
i
t
u
x
)
,
4
6
9
t
,
1
9
8
3
t
,
2
0
6
4
,
2
0
6
5
fo
r
c
o
lo
n
c
a
n
c
e
r
,
2
0
7
3
C
e
v
i
m
e
l
i
n
e
,
1
9
7
4
C
h
a
s
t
e
b
e
r
ry
(
Vi
t
e
x
a
g
n
u
s
-
c
a
s
t
u
s
o
r
VA
C
)
,
1
0
2
4
C
h
E
I
s
(
s
e
e
C
h
o
l
i
n
e
s
t
e
r
a
s
e
i
n
h
i
b
i
t
o
r
s
(
C
h
E
I
s
)
)
C
h
e
m
o
p
r
o
p
h
yl
a
x
i
s
,
fo
r
O
I
s
,
1
5
9
8
C
h
e
m
o
t
h
e
r
a
p
y
a
c
n
e
ifo
r
m–
e
r
yth
e
ma
t
o
u
s
r
a
s
h
,
1
9
7
8
fo
r
a
c
ut
e
le
uke
mia
,
1
9
9
7
fo
r
a
c
ut
e
my
e
lo
id
le
uke
mia
,
1
9
9
7
fo
r
a
c
ut
e
tub
ula
r
o
b
s
tru
c
t
io
n
,
1
9
9
2
fo
r
a
g
gr
e
s
s
iv
e
lymp
h
o
ma
s
,
2
0
4
2
in
A
L
L
,
2
0
1
6
,
2
0
1
7
t
a
n
d
a
lop
e
c
ia
,
1
9
7
6–
1
9
7
7
fo
r
A
M
L
,
2
0
2
6
a
n
d
a
n
e
mia
,
1
9
7
2
fo
r
a
r
r
hythmia
s
,
1
9
9
0
fo
r
a
ut
o
n
o
mic
n
e
ur
op
a
thy
,
1
9
8
7
fo
r
B
-
c
e
ll
lymp
h
o
ma
,
2
0
2
0–
2
0
2
1
o
n
b
o
n
e
ma
r
r
o
w
,
1
9
6
9
–
1
9
7
3
fo
r
c
a
r
dio
my
op
a
thy
,
1
9
8
7
–
1
9
8
8
a
n
d
c
a
r
dio
t
o
x
ic
ity
,
1
9
8
7
–
1
9
9
0
a
n
d
c
o
lo
ny
-
s
t
imula
t
in
g
fa
c
t
o
r
s
,
1
9
7
0–
1
9
7
1
a
n
d
c
r
a
nia
l
n
e
r
v
e
t
o
x
ic
ity
,
1
9
8
7
c
yt
o
t
o
x
ic
e
ffe
c
t
s
,
1
9
7
0
d
e
r
ma
t
o
lo
g
ic
imp
a
c
t
s
,
1
9
7
3
–
1
9
7
6
a
n
d
dia
r
r
h
e
a
,
1
9
7
6
do
s
a
g
e
r
e
g
ime
n
fo
r
intr
a
th
e
c
a
l,
2
0
1
6
t
do
s
in
g
in
in
fa
nt
s
a
n
d
y
o
un
g
c
h
ildr
e
n
,
2
0
0
7
a
n
d
dr
y
s
kin
,
1
9
7
8
a
n
d
e
s
op
h
a
g
it
is
,
1
9
7
5
a
n
d
e
s
op
h
a
gu
s
,
1
9
7
5
a
n
d
filgr
a
s
t
im
,
1
9
7
1
,
1
9
7
2
a
n
d
GI
tr
a
c
t
,
1
9
7
3
–
1
9
7
6
a
n
d
h
a
n
d
-
fo
o
t
s
yn
dr
o
me
,
1
9
7
8
h
e
ma
t
o
lo
g
ic
e
ffe
c
t
s
,
1
9
6
9
–
1
9
7
3
a
n
d
h
e
mo
r
r
h
a
g
ic
c
y
s
t
it
is
,
1
9
9
2
–
1
9
9
3
fo
r
H
L
,
2
0
4
1
hyp
e
r
s
e
n
s
it
iv
ity
r
e
a
c
t
io
n
s
,
1
9
8
0–
1
9
8
4
a
n
d
hyp
e
r
t
e
n
s
io
n
,
1
9
9
0
fo
r
in
do
le
nt
N
H
L
s
,
2
0
4
4
in
du
c
t
io
n
c
o
mb
in
a
t
io
n
,
2
0
1
4–
2
0
1
5
int
e
r
a
c
t
io
n
w
ith
r
a
dia
t
io
n
th
e
r
a
p
y
,
1
9
7
8
–
1
9
7
9
,
1
9
7
8
t
p. 2
2
9
5
p. 2
2
9
6
intr
a
th
e
c
a
l
p
r
op
hy
la
x
is
,
2
0
1
5
–
2
0
1
6
ir
r
it
a
nt
a
n
d
v
e
s
ic
a
nt
r
e
a
c
t
io
n
s
,
1
9
7
9
–
1
9
8
0
fo
r
la
r
g
e
c
e
ll
lymp
h
o
ma
s
,
2
0
2
1
a
n
d
life
-
thr
e
a
t
e
nin
g
n
e
utr
op
e
nia
,
1
9
7
0
lo
n
g
-
t
e
r
m
c
o
mp
lic
a
t
io
n
s
,
1
9
9
7
–
1
9
9
9
for lymphoblastic (T-cell) lymphoma, 2019–2020
and mucositis, 1974–1975
and myelosuppression, 1970–1972
and myocardial infarction, 1990
nausea and vomiting, 1973
nephrotoxicity, 1990–1992, 1991t
for neuroblastoma, 2003–2006
neurotoxicity, 1984–1987, 1985t
and neutropenia, 1970–1971
for NSCLC, 2063–2064
and oral cavity complications, 1973–1975
for osteosarcoma, 2008–2010
ototoxicity, 1987
for pediatric ALL, 2014
and pegfilgrastim, 1971
peripheral nerve toxicity, 1986
and peripheral neuropathy, 1986–1987
and pigment changes, 1977
and proteinuria, 1991–1992
and pulmonary functions, 1993–19936
for rhabdomyosarcoma, 2010–2011
skin and nail changes, 1977–1978
for specific organs, 1984–1987
and stomatitis, 1974–1975
and thrombocytopenia, 1970, 1972
venous thrombotic events, 1972–1973
and Wilms tumor, 2006–2008
and xerostomia, 1973–1974
Chitosan, 765t
Chlor-Trimeton (see Chlorpheniramine)
Chlorambucil (Leukeran), 470t, 1994t
for CLL, 2033
Chloramphenicol (Chloromycetin), 1325t, 1720
adverse effects of, 1333t
for RMSF, 1725
for tularemia, 1725
Chlordiazepoxide, 1737t
No comments:
Post a Comment
اكتب تعليق حول الموضوع